Gilead's Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
programs while keeping time-limited options on select assets like AB801, AB598, AB102 and a TNF inhibitor. Around the same time, Merck's newly approved Idvynso, a two-drug HIV regimen shown as non-inferior to Gilead's Biktarvy, underscored rising competitive pressure in Gilead's core HIV market just as it refines which external pipeline bets to keep or drop. We'll now examine how Gilead's tighter Arcus pipeline focus amid Idvynso's HIV entry could influence its long-term earnings and diversification narrative. Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Gilead Sciences Investment Narrative Recap To own Gilead, you have to believe its HIV engine plus new launches like Yeztugo and Livdelzi can offset pricing pressure and future patent cliffs while oncology matures into a real second pillar. The Arcus decision looks incremental near term, but Me
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026Business Wire
- Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]Seeking Alpha
- Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha]Seeking Alpha
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website